Navigation Links
Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/4/2008

VANCOUVER, Nov. 4 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that S. Wayne Kay, Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at 10:20 a.m. Eastern time at The New York Palace Hotel in New York City.

A Web cast of the presentation will be available at http://wsw.com/webcast/rrshq14/rbm.cn, during the event and will be archived and available on a link through the corporate Web site (http://www.responsebio.com) for 90 days.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack and congestive heart failure.

In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests worldwide and in 2008 entered into a strategic alliance with Roche Diagnostics to commercialize rapid cardiovascular tests worldwide.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for i
'/>"/>

SOURCE Response Biomedical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Response Biomedical Closes $5.1 Million Financing
2. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
3. Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference
4. Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing
5. Response Biomedical Announces Insider Participation in Current Financing
6. Hurricane Ike: World Vision Readies Supplies, Staff, Volunteers for Response
7. Monitoring immune responses in disease
8. Gustav: World Vision Teams Assist Evacuees in Jackson and Dallas, Prepare Response
9. Immune Response May Hinder Stem Cell Treatments
10. Study sees need for standardized evaluation of antibody response to HIV-1
11. Presidents Award Recognizes Hospitals Response to Bridge Collapse

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... , SAN FRANCISCO, Nov. 27 /PRNewswire-FirstCal...nounced that Blair Lambert, CFO/COO, will present ...l be held at the May Fair Hotel in London, England...T. ,, To listen to a live broadcast of The Gymb... please log on to www.gymboree.com, click on "Our ...
(Date:11/27/2009)... , NEUILLY-SUR-SEINE, France, Nov. 27 /PRNe...can professional cycling team dedicated to ethical...cling champions, announced today that it will beco...ansitions Optical as a new sponsor of the team. Tr...rer of adaptive eyewear, offering the most advance...
(Date:11/27/2009)... XenaCare Holdings has announ...rthritis Foundation, one of the largest nonprofit ...public health education. , ...naCare Holdings, Inc. (OTCBB: XCHO), a company spe... of consumer healthcare products, has announced to...
(Date:11/27/2009)...ing rates to bring unprecedented medical, economic.... 27 (HealthDay News) -- The number of people with...le over the next 25 years, a new study predicts. ,....1 million people with the disease, up from 23.7 m...treating people with diabetes will triple, the stu...
(Date:11/27/2009)... Voyant Health™ announc...gan) has licensed its TraumaCad Enterprise orthope...orkflow solution. , (PRWE...nced today that Spectrum Health (Grand Rapids, Mic...pedic templating solution and its TraumaCad Extend...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
...ards, Find Inspiration in Video Blogs on,Determine...r,couple,s video blogs documenting their efforts t... Pennsylvania Department of Health,s new tobacco,c...to quit smoking together, not just for themselves,...
...eth Campaign to Eliminate Compounded Hormones, WA...mpounding Pharmacists (IACP) today called on the A...AACE) and the North American,Menopause Society (NA...nt. In recent weeks, AACE, NAMS and other supposed...
...dividuals or families may have underlying speech d...ews) -- People with a personal or family history o...rare type of dementia that causes them to lose lan... and progressively impaired, even though the perso...
...ith the recent announcement by,the United States F...ng,safety review of Botox Cosmetic (botulinum toxi...to treat frown lines between the brows. Botox(R),C... In its recent communication, the FDA reports adve...
...Healthcare Services,Inc. (NYSE: AHS ), the nation...oday that Hala Moddelmog, President and Chief Exec...joined the company,s Board of,Directors., "Hala b...ng president and strategic leader of a successful,...
... first PDP to conduct ePrescribing Pilot Study, F...s a bill that would tie physicians, Medicare payme... Health Solutions, Inc. (NYSE: MHS ) today,announ...escriptions. The pilot program will also be used t...
Other Medicine News:Health News:American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals 2Health News:Learning Disabilities May Presage Later Language Problems 2Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 3Health News:Medco Launches Medicare Part D Initiative to Promote ePrescribing 2Health News:Medco Launches Medicare Part D Initiative to Promote ePrescribing 3Health News:Medco Launches Medicare Part D Initiative to Promote ePrescribing 4
(Date:11/25/2009)...lif., Nov. 25 ChemoCentryx, Inc....from the Company,s PROTECT-1 (the Prospective Rand...Trial) of Traficet-EN(TM) (CCX282-B) in patients w...d clinical efficacy with a favorable safety and to...ce of clinical efficacy in the reduction of diseas...
(Date:11/24/2009)...Nov. 24 Endologix, Inc. ...treatments for aortic disorders, announced today t...all proceedings in, the patent infringement lawsui... The motion was filed in the United States Distri... has requested that the stay remain in effect whil...
(Date:11/24/2009)...24 Anadys Pharmaceutical...ill present at the 21st Annual Piper Jaffray Healt...:00 a.m. EST (6:00 a.m. PST). The conference is b...land, Ph.D., President and Chief Executive Officer... its clinical development programs, ANA598 and ANA...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Blood Tests May Spot Colon Cancer 58044 1Blood Tests May Spot Colon Cancer 58044 2Blood Tests May Spot Colon Cancer 58044 3Blood Tests May Spot Colon Cancer 58044 4Prix Galien USA to Launch a Health Care Dialogue Among World Leading Innovators in Science Economics and Biotech 58040 1Prix Galien USA to Launch a Health Care Dialogue Among World Leading Innovators in Science Economics and Biotech 58040 2SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100 25 Yields 14215 1SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100 25 Yields 14215 2
...wing the candidate vaccine induced neutralizing a...ERFIELD, Ill., June 11 Baxter International,Inc. ..., 2008 issue of The,New England Journal of Medicin...avian influenza (H5N1) vaccine, CELVAPAN, met Phas...ty (generating a functional immune,response). This...
...JOLLA, Calif., June 11 Duska Therapeutics,Inc. (O...), announced today,that it has been granted an exc... Johns Hopkins University to develop and commercia...l cardiovascular drugs for the,treatment of heart ...s,expected to enter a Phase II clinical study late...
Other Medicine Technology:The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 2The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 3The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 5Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins 2Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins 3
Siemens Webcast
Siemens Webcast: Legislative Developments Impacting Cardiology Services Reimbursement
...ny pH catheters are designed for patient comfort a...re number marked at 5cm intervals and line marked ...models are available spanning most clinical needs ...e models with one or two sensors., ,Flexilog sing...
...ny pH catheters are designed for patient comfort a...re number marked at 5cm intervals and line marked ...models are available spanning most clinical needs ...e models with one or two sensors., ,A range of fo...
Medicine Products: